Nightingale Health’s Board of Directors resolved on new stock option program

Nightingale Health Plc | Stock Exchange Release | June 29, 2026 at 18:15:00 EEST

Nightingale Health Plc’s (“Nightingale Health”) Board of Directors has resolved to launch a new stock option program for Nightingale Health’s or its group companies’ employees or other key persons.

The purpose of Nightingale Health’s stock option programs is to bind the option holders to the company’s economic growth and the development of its market capitalization, as well as create a long-term relationship between the company and its option holders that benefits the company economically and operationally. The decision to launch the new stock option program was made based on the authorization granted by the Annual General Meeting held on 6 November 2025.

In accordance with the established practice for the company’s stock option rights, the right to subscribe for shares based on the new stock option program is earned upon reaching the following market capitalization steps, calculated based on the 45-day volume weighted average purchase price: EUR 500 million, 750 million, 1,000 million, 1,250 million and 1,500 million.

Each option right entitles the option holder to subscribe for one Series B share. The subscription price of each share is EUR 2.50 per share.

The total number of stock option rights that can be issued under the new stock option programs is 1,500,000, entitling holders to subscribe for a maximum of 1,500,000 Series B shares.

The share subscription period for the stock option program ends on 31 May 2036.

About Nightingale Health
Chronic diseases cause around 75% of deaths globally and place a growing burden on healthcare systems. The way to address this is preventive healthcare, but until recently the tools to detect disease risks at population scale have not existed. Nightingale Health has built them. The Nightingale Health Check is a blood-based risk detection test that identifies risks for multiple chronic diseases, including cardiovascular disease, type 2 diabetes, kidney disease, and fatty liver disease, from a single blood sample. It is designed to be applied population-wide, so healthcare systems can identify the people who would benefit most from preventive action before disease develops.

Nightingale Health's technology is validated in over 900 peer-reviewed scientific publications and is used in many of the world's leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 200,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/